Amoy Diagnostics

Amoy will develop its AmoyDx Pan Lung Cancer PCR Panel (9-in-1 Plus) as a companion diagnostic test for Haihe's MET kinase inhibitor Glumetinib.

AmoyDx aims to develop a companion diagnostic for Merck KGaA's non-small cell lung cancer treatment Tepmetko, which was recently approved in Japan.

The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.

Tokyo-based Eisai develops drugs primarily for the neurology and oncology markets, including treatments for Parkinson's disease and breast cancer.

AmoyDx and Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development.

The kit is approved for the qualitative detection of BRCA1 and BRCA2 mutations in patients with different cancer types including breast cancer.

AmoyDx's kit is designed to detect hotspot mutations/fusions in nine genes to help guide treatment decisions for non-small cell lung cancer patients.

The companion diagnostic for Pfizer's Xalkori identifies 14 ROS1 gene fusions by analyzing tumor messenger RNA from human tumor tissue or body fluids.